Mr. Andriole became President, CEO and a member of the Board of Directors of Chimerix in August 2023. During his nearly 25 years in the biotechnology industry, Mr. Andriole has demonstrated exceptional leadership in biopharmaceutical management with a focus on clinical development, corporate development, corporate strategy and corporate finance.
Prior to becoming President and CEO, Mr. Andriole was Chimerix’s Chief Business Officer and CFO from 2019 to 2023 during which time he helped guide a strategic shift from an infectious disease company, including the approval and monetization of TEMBEXA® for smallpox, to a rare disease oncology company. Prior to joining Chimerix, Mr. Andriole served as CFO and head of corporate development at Endocyte, Inc, where he was instrumental in directing the company into targeted radiopharmaceuticals during which the company grew from a $75 million market value to a successful sale to Novartis for $2.1 billion. Prior to Endocyte, Mr. Andriole spent 16 years at Eli Lilly and Company in a range of financial, marketing and global business development roles located in the United States and Europe. Mr. Andriole has worked on nine programs which have garnered NDA or BLA approvals across oncology, psychiatry and infectious disease, including blockbusters Pluvicto®, Cyramza®, Erbitux®, and Cymbalta®, among others.
His career maintains a consistent theme of leading teams with focused execution and delivering high quality results. He has executed over $10 billion in global business development transactions and has raised over $600 million of capital throughout his career. Mr. Andriole earned his BSBA from the Williams School of Business at Xavier University and his MBA from the Kelley School of Business at Indiana University.
What is Michael T. Andriole's net worth?
The estimated net worth of Michael T. Andriole is at least $5.21 million as of February 13th, 2025. Mr. Andriole owns 609,603 shares of Chimerix stock worth more than $5,206,010 as of April 22nd. This net worth estimate does not reflect any other investments that Mr. Andriole may own. Additionally, Mr. Andriole receives a salary of $820,000.00 as President, CEO, and Director at Chimerix. Learn More about Michael T. Andriole's net worth.
How old is Michael T. Andriole?
What is Michael T. Andriole's salary?
How do I contact Michael T. Andriole?
Has Michael T. Andriole been buying or selling shares of Chimerix?
Michael T. Andriole has not been actively trading shares of Chimerix during the last quarter. Most recently, Michael T. Andriole sold 7,370 shares of the business's stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $4.52, for a transaction totalling $33,312.40. Following the completion of the sale, the chief executive officer now directly owns 609,603 shares of the company's stock, valued at $2,755,405.56. Learn More on Michael T. Andriole's trading history.
Who are Chimerix's active insiders?
Are insiders buying or selling shares of Chimerix?
In the last twelve months, insiders at the biopharmaceutical company sold shares 9 times. They sold a total of 22,045 shares worth more than $92,241.70. The most recent insider tranaction occured on February, 13th when insider Allen S Melemed sold 3,065 shares worth more than $13,792.50. Insiders at Chimerix own 13.1% of the company.
Learn More about insider trades at Chimerix. Information on this page was last updated on 2/13/2025.
